Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks

Diabetes and Vascular Disease Research

Volumn 8, Issue 2, 2011, Pages 150-159

  Chacra, Antonio R ^a   Tan, Gerry H ^b   Ravichandran, Shoba ^c   List, James ^c   Chen, Roland ^c  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Cebu Doctors' University Hospital   (Philippines)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Dipeptidyl peptidase 4; DPP 4 inhibitor; HbA1C; Saxagliptin; Sulphonylurea; Type 2 diabetes mellitus

Indexed keywords

GLIBENCLAMIDE; HEMOGLOBIN A1C; PLACEBO; SAXAGLIPTIN;

ABDOMINAL PAIN; ACUTE HEART INFARCTION; ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BODY WEIGHT; BRAIN HEMORRHAGE; CARDIOGENIC SHOCK; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; FEMALE; GASTRITIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN; PHARYNGITIS; PHARYNGOTONSILLITIS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SUDDEN DEATH; TONSILLITIS; TRANSIENT ISCHEMIC ATTACK; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ADAMANTANE; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME;

EID: 79959211974     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164111404574     Document Type: Article

References (31)

1. Adler AI, Boyko EJ, Ahroni JH, Stensel V, Forsberg RC and Smith DG. Risk factors for diabetic peripheral sensory neuropathy. Results of the Seattle Prospective Diabetic Foot Study. Diabetes Care 1997; 20: 1162-1167.
2. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998; 316: 823-828. (Pubitemid 28112428)
3. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39: 1577-1583. (Pubitemid 26397370)
4. Krentz AJ and Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005; 65: 385-411. (Pubitemid 40227460)
5. Riddle M. Combining sulfonylureas and other oral agents. Am J Med 2000; 108(Suppl. 6a): 15S-22S.
6. Brown JB, Nichols GA and Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004; 27: 1535-1540. (Pubitemid 38857422)
7. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443. (Pubitemid 44903747)
8. Amori RE, Lau J and Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and metaanalysis. JAMA 2007; 298: 194-206. (Pubitemid 47057766)
9. Monami M, Iacomelli I, Marchionni N and Mannucci E. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a metaanalysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2010; 20: 224-235.
10. Ahrén B. Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes. Expert Opin Emerg Drugs 2008; 13: 593-607.
11. Richter B, Bandeira-Echtler E, Bergerhoff K and Lerch C. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag 2008; 4: 753-768.
12. Seck T, Nauck M, Sheng D, Sunga S, Davies MJ, Stein PP, et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract 2010; 64: 562-576.
13. Nauck MA, Meininger G, Sheng D, Terranella L and Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007; 9: 194-205.
14. Schweizer A, Couturier A, Foley JE and Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetes. Diabet Med 2007; 24: 955-961. (Pubitemid 47301637)
15. Bolli G, Dotta F, Colin L, Minic B and Goodman M. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Obes Metab 2009; 11: 589-595.
16. Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B, Byiers S, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009; 11: 157-166.
17. Williams-Herman D, Johnson J, Teng R, Luo E, Davies MJ, Kaufman KD, et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin 2009; 25: 569-583.
18. Foley JE and Sreenan S. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes. Horm Metab Res 2009; 41: 905-909.
19. Rosenstock J, Niggli M and Maldonado-Lutomirsky M. Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009; 11: 571-578.
20. Göke B, Hershon K, Kerr D, Calle Pascual A, Schweizer A, Foley J, et al. Efficacy and safety of vilodagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes: comparison with metformin. Horm Metab Res 2008; 40: 892-895.
21. Onglyza (package insert). Princeton, NJ/Wilmington, DE: Bristol-Myers Squibb Company/AstraZeneca Pharmaceuticals LP, 2009.
22. Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J and Chen R. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 2009; 63: 1395-1406.
23. Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004; 64: 1339-1358. (Pubitemid 38916346)
24. DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773-795.
25. Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M and Brunetti P. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004; 89: 6068-6076. (Pubitemid 39628416)
26. Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR and Charbonnel BH. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004; 27: 141-147. (Pubitemid 38196723)
27. Pareek A, Chandurkar NB, Salkar HR, Borkar MS and Tiwari D. Evaluation of efficacy and tolerability of glimepiride and metformin combination: a multicentric study in patients with type 2 diabetes mellitus, uncontrolled on monotherapy with sulfonylurea or metformin. Am J Ther Epub ahead of print (accessed 15 February 2011).
28. Ceriello A, Johns D, Widel M, Eckland DJ, Gilmore KJ and Tan MH. Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes. Diabetes Care 2005; 28: 266-272. (Pubitemid 40170924)
29. Makimattila S, Nikkila K and Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia 1999; 42: 406-412. (Pubitemid 29148398)
30. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H and Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007; 9: 733-745. (Pubitemid 47261855)
31. Garber AJ, Foley JE, Banerji MA, Ebeling P, Gudbjörnsdottir S, Camisasca RP, et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab 2008; 10: 1047-1056.